A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway

Journal of Medicinal Chemistry

Volumn 59, Issue 19, 2016, Pages 9062-9079

  Wang, Ya Dan ^a   Bao, Xiu Qi ^a   Xu, Song ^a   Yu, Wen Wen ^a   Cao, Sheng Nan ^a   Hu, Jin Ping ^a   Li, Yan ^a   Wang, Xiao Liang ^a   Zhang, Dan ^a   Yu, Shi Shan ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXY 4 METHOXYPHENYL) 3 METHYLBUTAN 1 ONE; 1 (2 HYDROXY 4,6 DIMETHOXYPHENYL) 3 METHYLBUTAN 1 ONE; 1 (2,4 DIHYDROXY 6 METHOXYPHENYL) 3 METHYLBUTAN 1 ONE; 1 (2,4,6 TRIHYDROXYPHENYL)ETHANONE; 1 (2,4,6 TRIHYDROXYPHENYL)PENTAN 1 ONE; 1 (2,4,6 TRIMETHOXYPHENYL) 3 METHYLBUTAN 1 ONE; 1 (4 HYDROXYPHENYL) 3 METHYLBUTAN 1 ONE; 2 (4 METHYLPIPERAZIN 1 YL) 1 (2,4,6 TRIMETHOXYPHENYL)ETHANONE; 2 (PIPERIDIN 1 YL) 1 (2,4,6 TRIMETHOXYPHENYL)ETHANONE; 2 MORPHOLINO 1 (2,4,6 TRIMETHOXYPHENYL)ETHANONE; 2 [(2,4,6 TRIMETHOXYBENZYL)AMINO]ACETIC ACID; 2 [(2,4,6 TRIMETHOXYBENZYL)AMINO]PENTANEDIOIC ACID; 2 [(2,4,6 TRIMETHOXYBENZYL)AMINO]PROPANOIC ACID; 2 [(2,4,6 TRIMETHOXYBENZYL)AMINO]SUCCINIC ACID; 3 (1H IMIDAZOL 5 YL) 2 [(2,4,6 TRIMETHOXYBENZYL)AMINO]PROPANOIC ACID; 3 HYDROXY 2 [(2,4,6 TRIMETHOXYBENZYL)AMINO]PROPANOIC ACID; 3 PHENYL 2 [(2,4,6 TRIMETHOXYBENZYL)AMINO]PROPANOIC ACID; 4 (PIPERIDIN 1 YL) 1 (2,4,6 TRIHYDROXYPHENYL)BUTAN 1 ONE HYDROCHLORATE; 4 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL] 1 (2,4,6 TRIHYDROXYPHENYL)BUTAN 1 ONE HYDROCHLORATE; 4 [CYCLOHEXYL(METHYL)AMINO] 1 (2,4,6 TRIHYDROXYPHENYL)BUTAN 1 ONE HYDROCHLORATE; 4 [[3,5 DIHYDROXY 2 (3 METHYLBUTANOYL)PHENOXY]METHYL] 3 PHENYL FUROXAN; ANTIINFLAMMATORY AGENT; ANTIPARKINSON AGENT; CURCUMIN; N (2,4,6 TRIMETHOXYBENZYL)PROPAN 2 AMINE; N BUTYL 2,4,6 TRIHYDROXYBENZAMIDE; N ISOPROPYL 2,4,6 TRIHYDROXYBENZAMIDE; PHLOROGLUCINOL DERIVATIVE; PROTEIN KINASE P60; UNCLASSIFIED DRUG; UNINDEXED DRUG; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3-HYDROXY-2-((2,4,6-TRIMETHOXYBENZYL)AMINO)PROPANOIC ACID; NEUROPROTECTIVE AGENT; PHLOROGLUCINOL; PROTEIN TYROSINE KINASE; SERINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROCESS OPTIMIZATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PARKINSON DISEASE, SECONDARY; PATHOLOGY; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; MALE; MICE, INBRED ICR; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; PHLOROGLUCINOL; SERINE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84991396164     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00976     Document Type: Article

References (34)

1. Lozano, A. M.; Lang, A. E.; Hutchison, W. D.; Dostrovsky, J. O. New developments in understanding the etiology of Parkinson's disease and in its treatment Curr. Opin. Neurobiol. 1998, 8, 783-790 10.1016/S0959-4388(98)80122-0
2. Ferreira, J. J.; Rocha, J. F.; Falcao, A.; Santos, A.; Pinto, R.; Nunes, T.; Soares-da-Silva, P. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease Eur. J. Neurol. 2015, 22, 815-825 10.1111/ene.12666
3. Schapira, A. H. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects CNS Drugs 2011, 25, 1061-1071 10.2165/11596310-000000000-00000
4. Huot, P.; Johnston, T. H.; Lewis, K. D.; Koprich, J. B.; Reyes, M. G.; Fox, S. H.; Piggott, M. J.; Brotchie, J. M. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset Neuropharmacology 2014, 82, 76-87 10.1016/j.neuropharm.2014.01.012
5. Yamamoto, M.; Schapira, A. H. Dopamine agonists in Parkinson's disease Expert Rev. Neurother. 2008, 8, 671-677 10.1586/14737175.8.4.671
6. Henchcliffe, C.; Severt, W. L. Disease modification in Parkinson's disease Drugs Aging 2011, 28, 605-615 10.2165/11591320-000000000-00000
7. Shoulson, I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism Ann. Neurol. 1998, 44, S160-S166 10.1002/ana.410440724
8. Athauda, D.; Foltynie, T. The ongoing pursuit of neuroprotective therapies in Parkinson disease Nat. Rev. Neurol. 2015, 11, 25-40 10.1038/nrneurol.2014.226
9. Dauer, W.; Przedborski, S. Parkinson's disease: mechanisms and models Neuron 2003, 39, 889-909 10.1016/S0896-6273(03)00568-3
10. Gao, H. M.; Hong, J. S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression Trends Immunol. 2008, 29, 357-365 10.1016/j.it.2008.05.002
11. Liu, Z.; Chen, H. Q.; Huang, Y.; Qiu, Y. H.; Peng, Y. P. Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP(+)-induced dopaminergic neuronal loss Brain, Behav., Immun. 2016, 51, 131-143 10.1016/j.bbi.2015.08.006
12. Van der Perren, A.; Macchi, F.; Toelen, J.; Carlon, M. S.; Maris, M.; de Loor, H.; Kuypers, D. R.; Gijsbers, R.; Van den Haute, C.; Debyser, Z.; Baekelandt, V. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease Neurobiol. Aging 2015, 36, 1559-1568 10.1016/j.neurobiolaging.2015.01.014
13. Wang, Q.; Liu, Y.; Zhou, J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target Transl. Neurodegener. 2015, 4, 19 10.1186/s40035-015-0042-0
14. Bartels, A. L.; Willemsen, A. T.; Doorduin, J.; de Vries, E. F.; Dierckx, R. A.; Leenders, K. L. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat. Disord. 2010, 16, 57-59 10.1016/j.parkreldis.2009.05.005
15. Imamura, K.; Hishikawa, N.; Sawada, M.; Nagatsu, T.; Yoshida, M.; Hashizume, Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathol. 2003, 106, 518-526 10.1007/s00401-003-0766-2
16. Rees, K.; Stowe, R.; Patel, S.; Ives, N.; Breen, K.; Clarke, C. E.; Ben-Shlomo, Y. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies Cochrane Database Syst. Rev. 2011, CD008454 10.1002/14651858.CD008454.pub2
17. Lindholm, D.; Makela, J.; Di Liberto, V.; Mudo, G.; Belluardo, N.; Eriksson, O.; Saarma, M. Current disease modifying approaches to treat Parkinson's disease Cell. Mol. Life Sci. 2016, 73, 1365-1379 10.1007/s00018-015-2101-1
18. Tatsuta, K. Preparation of dihydrobenzopyrans as intermediates for sideroxylonal and physiological active substances. PCT Int. Appl. JP 2000186084, 2000.
19. Lafon, L. (2,4,6-Trimethoxyphenyl)-(3-piperidinopropyl)-ketone derivatives. PCT Int. Appl. US 4705795, 1987.
20. Du, D.; Yan, J.; Ren, J.; Lv, H.; Li, Y.; Xu, S.; Wang, Y.; Ma, S.; Qu, J.; Tang, W.; Hu, Z.; Yu, S. Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo J. Med. Chem. 2013, 56, 97-108 10.1021/jm301248y
21. Dewick, P. M. Benzyl p-toluenesulfonate as an O-benzylating agent for the protection of phenols Synth. Commun. 1981, 11, 853-857 10.1080/00397918108065666
22. Kim, G. Y.; Kim, J.; Lee, S. H.; Kim, H. J.; Hwang, K. J. Synthesis and fragmentation of furoxanaldehydes in the gas phase for nanopatterned alkyne formation on a solid surface Bull. Korean Chem. Soc. 2009, 30, 459-463 10.5012/bkcs.2009.30.2.459
23. Zhao, M.; Zhou, A.; Xu, L.; Zhang, X. The role of TLR4-mediated PTEN/PI3K/AKT/NF-κB signaling pathway in neuroinflammation in hippocampal neurons Neuroscience 2014, 269, 93-101 10.1016/j.neuroscience.2014.03.039
24. Alexaki, V. I.; Charalampopoulos, I.; Kampa, M.; Vassalou, H.; Theodoropoulos, P.; Stathopoilos, E. N.; Hatzoglou, A.; Gravanis, A.; Castanas, E. Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation FASEB J. 2004, 18, 1594-1596 10.1096/fj.04-1495fje
25. Wang, G.; Shi, Y.; Jiang, X.; Leak, R. K.; Hu, X.; Wu, Y.; Pu, H.; Li, W. W.; Tang, B.; Wang, Y.; Gao, Y.; Zheng, P.; Bennett, M. V.; Chen, J. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 2853-2858 10.1073/pnas.1501441112
26. Fragoso, R.; Barata, J. T. Kinases, tails and more: regulation of PTEN function by phosphorylation Methods 2015, 77-78, 75-81 10.1016/j.ymeth.2014.10.015
27. Li, Z.; Dong, X.; Wang, Z.; Liu, W.; Deng, N.; Ding, Y.; Tang, L.; Hla, T.; Zeng, R.; Li, L.; Wu, D. Regulation of PTEN by Rho small GTPases Nat. Cell Biol. 2005, 7, 399-404 10.1038/ncb1236
28. Jyothi, H. J.; Vidyadhara, D. J.; Mahadevan, A.; Philip, M.; Parmar, S. K.; Manohari, S. G.; Shankar, S. K.; Raju, T. R.; Alladi, P. A. Aging causes morphological alterations in astrocytes and microglia in human substantia nigra pars compacta Neurobiol. Aging 2015, 36, 3321-3333 10.1016/j.neurobiolaging.2015.08.024
29. Lull, M. E.; Block, M. L. Microglial activation and chronic neurodegeneration Neurotherapeutics 2010, 7, 354-365 10.1016/j.nurt.2010.05.014
30. Paul, R.; Zhang, Z. G.; Eliceiri, B. P.; Jiang, Q.; Boccia, A. D.; Zhang, R. L.; Chopp, M.; Cheresh, D. A. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke Nat. Med. 2001, 7, 222-227 10.1038/84675
31. Lu, Y.; Yu, Q.; Liu, J. H.; Zhang, J.; Wang, H.; Koul, D.; McMurray, J. S.; Fang, X.; Yung, W. K.; Siminovitch, K. A.; Mills, G. B. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades J. Biol. Chem. 2003, 278, 40057-40066 10.1074/jbc.M303621200
32. Socodato, R.; Portugal, C. C.; Domith, I.; Oliveira, N. A.; Coreixas, V. S.; Loiola, E. C.; Martins, T.; Santiago, A. R.; Paes-de-Carvalho, R.; Ambrosio, A. F.; Relvas, J. B. c-Src function is necessary and sufficient for triggering microglial cell activation Glia 2015, 63, 497-511 10.1002/glia.22767
33. Tai, W.; Ye, X.; Bao, X.; Zhao, B.; Wang, X.; Zhang, D. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models Neuropharmacology 2013, 75, 201-212 10.1016/j.neuropharm.2013.07.020
34. Bao, X. Q.; Kong, X. C.; Qian, C.; Zhang, D. FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models Neuroscience 2012, 202, 396-40 10.1016/j.neuroscience.2011.11.036